web analytics
4.7 C
Munich
Tuesday, November 29, 2022

Running With International Stem Cell Corp (OTCMKTS:ISCO)

International Stem Cell Corp (OTCMKTS:ISCO) is one volatile stock that recently made an explosive move up off its $4 base to highs over $6 before coming back to where it started.

The Company recently completed a 150 for 1 reverse stock split with temporarily changed the ticker symbol to ISCOD for 20 days before reverting back to ISCO.

International Stem Cell Corp (OTCMKTS:ISCO) is a California-based biotechnology company developing novel stem cell-based therapies currently focused on obtaining regulatory approval for their Parkinson’s disease treatment in Australia, as well as in the US.

ISCO’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation.

hpSCs offer the potential to create the first true stem cell bank, UniStemCell(TM). ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and stem cell-based skin care products through its subsidiary Lifeline Skin Care.

Last year ISCO announced that the Court of Justice of the European Union has ruled in favor of the Company and that the Company’s core technology patent applications are not covered by the prohibition on patenting embryonic stem cells. This ruling confirms the opinion of the Advocate General published in July 2014.

At issue were two patent applications filed by the Company, GB20060021068 and GB20060021069, which were rejected by the United Kingdom Intellectual Property Office (UKIPO) on the grounds that the disclosed technology, parthenogenetic stem cells and methods of making these stem cells, was excluded from patentability by the EU Directive on Legal Protection of Biotechnological Inventions.

ISCO is fully reporting OTCBB with significant revenues of $5.2 million for the 9 months ended September 30, 2014 up from $4.4 million last year. The Company stands to benefit from strategic alliances with Rohto Pharmaceutical Co., LTD. and Grupo Venta Interncional S.A de C.V will help grow revenue in newer markets.

To Find out the inside Scoop on ISCO Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

In September ISCO said it had entered into the second phase of the existing Research Agreement with Rohto Pharmaceutical Co., Ltd. a global Japanese pharmaceutical company. After successfully completing preliminary studies of ISCO’s human parthenogenetic neural stem cells (hpNSCs)

Rohto acknowledged that ISCO’s proprietary cells demonstrate consistent high quality and are suitable for further use in Rohto’s research. If Rohto successfully demonstrates hpNSCs’ efficacy in rodent models, which could lead to a possible treatment of a variety of degenerative eye disorders, Rohto will enter into negotiations of a definitive license agreement with ISCO in order to license ISCO’s proprietary technology for therapeutic and commercial use.

“Based on hpNSCs known performance in various animal models we expect that in the next four months Rohto will be able to demonstrate the efficacy of these stem cells in treating retinal degenerative disorders,” said Ruslan Semechkin, Ph.D., Chief Scientific Officer of ISCO.

On September 30 ISCO announced the Company’s scientific team has developed a robust innovative technology to generate functional articular cartilage from the patient’s own skin or adipose tissue to treat osteoarthritis. This breakthrough technology may allow ISCO to not only address the therapeutic needs of patients suffering from osteoarthritic knee joints, but to also treat those with shoulder joints and intervertebral spinal disk osteoarthritis.

Despite the high prevalence of osteoarthritis, currently there is a lack of an effective treatment for this disease. ISCO developed and successfully tested a scalable system that permits the generation of functional human cartilage tissue with superior mechanical properties and, more importantly, the capacity to provide greater stability than other tissue that is currently available for the treatment of osteoarthritis.

ISCO’s chief scientific officer, Ruslan Semechkin, PhD said “While we are working on obtaining regulatory approval for the Parkinson’s disease treatment in Australia, as well as in the US, we are also pursuing a number of other therapeutic indications including osteoarthritis, which can potentially be treated with the patient’s own cells,”

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $7 million market valuation ISCO does have some assets on the books and growing revenues but they are also quickly developing a debt problem including $3.5 million in Accrued liabilities and Related party payables. But ISCO is an exciting story developing in small caps; the Company develops novel stem cell-based therapies and is currently focused on obtaining regulatory approval for their Parkinson’s disease treatment in Australia, as well as in the US. We will be updating on ISCO when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ISCO.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in ISCO either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.